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Abstract
Purpose: Gender-afﬁrming surgeries and hormone therapy are medically necessary treatments to alleviate gen-
der dysphoria; however, signiﬁcant gaps exist in the research and clinical literature on surgery utilization and age
of hormone therapy initiation among transgender adults.
Methods: We conducted a retrospective review of electronic health record data from a random sample of 201
transgender patients of ages 18–64 years who presented for primary care between July 1, 2010 and June 30, 2015
(inclusive) at an urban community health center in Boston, MA. Fifty percent in our analyses were trans masculine
(TM), 50% trans feminine, and 24% reported a genderqueer/nonbinary gender identity. Regression models were
ﬁt to assess demographic, gender identity-related, sexual history, and mental health correlates of gender-
afﬁrming surgery and of age of hormone therapy initiation.
Results: Overall, 95% of patients were prescribed hormones by their primary care provider, and the mean age of
initiation of masculinizing or feminizing hormone prescriptions was 31.8 years (SD = 11.1). Younger age of initi-
ation of hormone prescriptions was associated with being TM, being a student, identifying as straight/heterosex-
ual, having casual sexual partners, and not having past alcohol use disorder. Approximately one-third (32%) had a
documented history of gender-afﬁrming surgery. Factors associated with increased odds of surgery were older
age, higher income levels, not identifying as bisexual, and not having a current psychotherapist.
Conclusion: This study extends our understanding of prevalence and factors associated with gender-afﬁrming
treatments among transgender adults seeking primary care. Findings can inform future interventions to expand
delivery of clinical care for transgender patients.
Keywords: barriers to care; gender-afﬁrming hormone therapy; gender-afﬁrming surgery; mental health; sexual
health; transgender
Introduction
Gender-afﬁrming hormone therapy and surgeries1,2
are deemed medically necessary treatments for gender
dysphoria by the American Medical Association and
other clinical policy-setting organizations.3 Access to
gender-afﬁrming hormone therapy and surgeries is as-
sociated with improvements in psychological function-
ing and quality of life among transgender adults,4–6 and
decreased risk of suicidal ideation and substance use
disorders.7,8 Nevertheless, transgender adults continue
to experience numerous barriers to accessing and re-
ceiving gender-afﬁrming medical and surgical care,
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including harassment and denial of treatment by provid-
ers, fear of mistreatment based on their gender identity
resulting in not seeking needed healthcare, lack of ﬁnan-
cial resources needed to access care, and ongoing denial of
insurance coverage for gender-afﬁrming hormone ther-
apy and surgical procedures.9,10 Health professionals
typically receive minimal training in core clinical com-
petencies related to transgender health, and healthcare
settings often fail to provide inclusive, afﬁrming environ-
ments for transgender patients.11 Because of barriers to
accessing gender-afﬁrming medical and surgical care,
transgender people are often relegated to unsafe medi-
cally unmonitored hormone use and other body modiﬁ-
cations (e.g., unmonitored silicone injections) to afﬁrm
their gender and alleviate distress.12–18
Little is known about factors associated with gender-
afﬁrming surgery and age of initiation of hormone
therapy among transgender adults. Transgender adults
vary signiﬁcantly in their access to and selection of pos-
sible hormone therapy, surgical procedures, or both
to afﬁrm their gender through personalized care
plans.2,19–21 Transgender people also vary across the
lifespan with regard to the age at which they initiate
gender-afﬁrming medical care,2 and factors inﬂuencing
individual variability in the age of hormone initiation
are poorly understood. Existing research on barriers
to transgender healthcare access has relied largely on
participant self-report rather than direct methods
such as medical documentation.10 One such study
using self-report identiﬁed treatment costs and lack
of qualiﬁed providers as barriers to optimal care, and
found that transgender respondents >50 years old
and those in committed relationships were less likely
to report plans for future gender-afﬁrming hormone
therapy.22
There remain signiﬁcant gaps in the literature re-
garding the relationship between demographics, gen-
der identity, sexual history, and mental health to
hormone therapy initiation and surgery utilization
among transgender adults. To address these gaps, this
study used a retrospective electronic health record
(EHR) review to (1) assess the prevalence and distribu-
tion of gender-afﬁrming hormone therapy and surger-
ies among transgender adults at a Boston community
health center with specialized care for sexual and gen-
der minority populations and (2) examine the associa-
tion of gender-afﬁrming surgery utilization and age of
hormone therapy initiation with demographics, gender
identity, sexual history, and mental health in this tradi-
tionally underserved population.
Methods
Study participants and procedures
We conducted a retrospective review of EHR data from a
random sample of 201 transgender patients of ages 18–
64 years who presented for one or more healthcare vis-
it(s) between July 1, 2010 and June 30, 2015 (inclusive)
at an urban community health center in Boston, MA,
specializing in LGBT (lesbian, gay, bisexual, and trans-
gender) healthcare.23,24 This study period was the 5-
year time frame immediately before beginning the
EHR review process. Patients were identiﬁed as trans-
gender by automated query based on a standardized
ﬂag system in the EHR used to designate all transgender-
identiﬁed patients at the health center. The sample was
drawn from the pool of all 1683 transgender-identiﬁed
patients of 18 years or older who had presented for
care within the 5-year study period, using an automated
simple random sampling algorithm.25 Data were treated
as a cross-sectional sample. Variables related to demo-
graphics, gender identity, sexual history, and mental
health were extracted through a combination of auto-
mated query and manual audit methods from the
EHR. Variables extracted by automated query were sys-
tematically conﬁrmed by manual audit of EHR visit
notes. Variables of interest were operationally deﬁned
with speciﬁc parameters and collected through prespeci-
ﬁed systematic protocols to minimize potential bias re-
lated to recall, missing data, and other factors during
the EHR data extraction process.26,27 The study was ap-
proved by the health center’s Institutional Review Board.
Variables and operationalization
Outcomes. The two outcome variables in this study
were (1) history of any gender-afﬁrming surgery (yes,
no) and (2) age of gender-afﬁrming hormone therapy
initiation (years). We determined age of hormone ther-
apy initiation for each participant by manual EHR audit
to assess the date of ﬁrst hormone therapy, which was
systematically documented for transgender patients in
the health center’s EHR. History of any gender-afﬁrming
surgery (chest construction, breast augmentation, facial
feminization, phalloplasty, metoidioplasty, vaginoplasty,
hysterectomy, oophorectomy, orchiectomy, or other
gender-afﬁrming procedures) was determined by man-
ual EHR audit, as these surgical procedures were also
systematically documented in the EHR.
Statistical predictors. We assessed statistical predictors
of age of hormone therapy initiation and of any gender-
afﬁrming surgery in four areas: (1) demographics, (2)
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gender identity-related characteristics, (3) sexual history,
and (4) mental health. Presence or absence of these
characteristics was determined from the EHR for the
5-year study period through a combination of auto-
mated queries and manual chart audit. The statistical
predictors are detailed in Tables 1–4.
Statistical analysis
Univariate statistics were used to examine the distribu-
tions of all variables (mean, median, standard deviation,
frequency, and proportion) overall and stratiﬁed by gen-
der identity: trans masculine (TM) versus trans feminine
(TF). Following descriptive statistics, bivariate analyses
were conducted by gender identity to compare TM ver-
sus TF patients. Mann–Whitney U tests were used to as-
sess median differences for non-normally distributed
continuous variables (i.e., ‘‘current age’’ and ‘‘age of med-
ical gender afﬁrmation’’). Pearson’s chi-square (w2) tests
with Yates’ correction were used to examine any differ-
ences in expected and observed proportions by gender
identity. Where sparse data caused expected counts to
be <5, Fisher’s exact tests were utilized to obtain exact
p-values to accompany w2 test statistics.
Multivariable regression analyses were conducted
with variables that had >85% completeness and were
selected based on clinical hypotheses. Among patients
in the sample, 56 (27.9%) did not have complete data
for all desired variables and were excluded from the
multivariable regression procedures. Thus, multivari-
able regression analyses were restricted to 145 patients
(72.1% of the original sample: a random distribution of
73 TM and 72 TF patients). To assess how sample char-
acteristics of these 145 eligible participants compared
with the health center’s overall pool of 1683 transgen-
der patients, we conducted w2 analyses comparing the 2
groups across each race/ethnicity category and found
no statistically signiﬁcant differences at the p< 0.05
level in the proportion of patients who identiﬁed as
‘‘white,’’ ‘‘black/African American,’’ ‘‘Latinx/Hispanic,’’
‘‘multiracial,’’ ‘‘other,’’ or ‘‘not indicated.’’ A ‘‘dummy’’
variable coding exclusion versus inclusion (missing
vs. not missing) in the multivariable analyses was cre-
ated and analyzed as a bivariate against each regression
outcome to ascertain whether exclusion introduced
bias. In these sensitivity analyses, this covariate did
not reach statistical signiﬁcance in any of the models.
Table 1. Demographics
Variable
TM
(n = 73)
TF
(n = 72)
Total
(N = 145)
TM vs.
TF, p
Age in years
Mean (SD) 27.9 (6.9) 35.7 (13.7) 31.8 (11.5)
Median 25.0 30.0 27.0 0.001
Range 19–50 21–64 19–64
Population age strata in sample, n (%)
18–25 years 40 (54.8) 24 (33.3) 64 (44.1) <0.001
26–49 years 32 (43.8) 33 (45.8) 65 (44.8)
50+ years 1 (1.4) 15 (20.8) 16 (11.0)
Race/ethnicity, n (%)
White 55 (75.3) 60 (83.3) 115 (79.3) 0.235
Black/African American 5 (6.8) 1 (1.4) 6.0 (4.1)
Latinx/Hispanic 2 (2.7) 3 (4.2) 5.0 (3.4)
Multiracial 7 (9.6) 5 (6.9) 12.0 (8.3)
Other 3 (4.1) 2 (2.8) 5.0 (3.4)
Not indicated 1 (1.4) 1 (1.4) 2.0 (1.4)
Employment, n (%)
Working full or part time 51 (69.9) 48 (66.7) 99 (68.3) 0.200
Not working (unemployed,
retired, or disabled)
10 (13.7) 17 (23.6) 27 (18.6)
Student 12 (16.4) 7 (9.7) 19 (13.1)
Income, n (%) 0.587
At or below poverty level 29 (39.7) 31 (43.1) 60 (41.4)
100–200% of poverty level 8 (11.0) 11 (15.3) 19 (13.1)
200–300% of poverty level 17 (23.3) 11 (15.3) 28 (19.3)
> 300% of poverty level 17 (23.3) 19 (26.4) 36 (24.8)
Not indicated 2 (2.7) 0 (0.0) 2 (1.4)
Bold indicates statistical signiﬁcance ( p < 0.05). Reported p-values are
from Fisher’s exact tests wherein cell sizes are small (<5). Response rate
was 100% for all variables except where table states ‘‘Not indicated.’’
SD, standard deviation; TF, trans feminine; TM, trans masculine.
Table 2. Gender Identity-Related Characteristics
Variable TM (n= 73), n (%) TF (n= 72), n (%) Total (N =145), n (%) TM vs. TF, p
Gender identity when established care at community health center <0.001
Female 5 (6.8) 49 (68.1) 54 (37.2)
Male 49 (67.1) 7 (9.7) 56 (38.6)
Genderqueer/nonbinary 19 (26.0) 16 (22.2) 35 (24.1)
Hormones prescribed by primary care provider 69 (94.5) 69 (95.8) 138 (95.2) 1.000
Current medically unmonitored hormone use 0 (0.0) 3 (4.2) 3 (2.1) 0.120
Any past medically unmonitored hormone use 0 (0.0) 6 (8.3) 6 (4.1) 0.013
Any gender-affirming surgery 27 (37.0) 20 (27.8) 47 (32.4) 0.314
Age of hormone therapy initiation
Mean (SD) 27.9 (7.1) 33.3 (13.2) 31.8 (11.1)
Median 24.0 27.0 27.0 0.001
Range 8–50 15–64 8–64
Bold indicates statistical signiﬁcance ( p < 0.05). Reported p-values are from Fisher’s exact tests wherein cell sizes are small (<5). Response rate was
100% for all variables except where table states ‘‘Not indicated.’’
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To increase power, the sample was analyzed in aggre-
gate and not stratiﬁed by gender identity. Gender iden-
tity was included as a covariate. Model building initially
focused on examining bivariate models for each of the
variables listed in Tables 1–4 to identify those with sta-
tistical signiﬁcance. Factors signiﬁcant at the p< 0.05
level were entered into a multivariable model, and var-
iable selection for independent associations was imple-
mented using the backward elimination method. All
signiﬁcant variables were entered into the equation
and the least useful variables were eliminated one at a
time using the smallest w2 to remove, to a threshold
for inclusion of p < 0.05.28
For the binary outcome variable, multivariable logis-
tic regression models were ﬁt to examine factors associ-
ated with history of gender-afﬁrming surgery. For the
regression on history of gender-afﬁrming surgery, the
variable ‘‘current age’’ was a signiﬁcant bivariate due to
its strong correlation with a number of other variables
and was, therefore, entered after conducting model se-
lection with the other variables. The inference for the
ﬁnal model for history of gender-afﬁrming surgery did
not differ from the model before adding the ‘‘current
age’’ variable. The ‘‘current age’’ variable was excluded
from the regression on ‘‘age of hormone therapy initia-
tion’’ due to its especially strong correlation in that case.
Table 3. Sexual Orientation and History
Variable
TM
(n= 73),
n (%)
TF
(n =72),
n (%)
Total
(N =145),
n (%)
TM vs.
TF, p
Sexual orientation 0.019
Bisexual 9 (12.3) 22 (30.6) 31 (21.4)
Lesbian, gay, or homosexual 14 (19.2) 15 (20.8) 29 (20.0)
Straight or heterosexual 15 (20.5) 9 (12.5) 24 (16.6)
Something else 31 (42.5) 18 (25.0) 49 (33.8)
Does not know 4 (5.5) 8 (11.1) 12 (8.3)
Primary sex partner 48 (65.8) 42 (58.3) 90 (62.1) 0.454
Casual sex partner(s) 5 (6.8) 5 (6.9) 10 (6.9) 0.982
Any STI diagnosis 13 (17.8) 7 (9.7) 20 (13.8) 0.242
Bold indicates statistical signiﬁcance ( p < 0.05). Reported p-values are from Fisher’s exact tests wherein cell sizes are small (<5). Response rate was
100% for all variables except where table states ‘‘Not indicated.’’
Table 4. Mental Health
Variable TM (n= 73), n (%) TF (n= 72), n (%) Total (N = 145), n (%) TM vs. TF, p
Lifetime substance use 59 (80.8) 54 (75.0) 113 (77.9) 0.519
Current alcohol use 52 (71.2) 49 (68.1) 101 (69.7) 0.814
Past alcohol use 7 (9.6) 6 (8.3) 13 (9.0) 0.791
Current cannabis use 26 (35.6) 22 (30.6) 48 (33.1) 0.638
Any assessed psychiatric diagnoses 45 (61.6) 38 (52.8) 83 (57.2) 0.362
Lifetime substance use disorder 13 (17.8) 17 (23.6) 30 (20.7) 0.511
Current alcohol use disorder 3 (4.1) 8 (11.1) 11 (7.6) 0.129
Past alcohol use disorder 5 (6.8) 5 (6.9) 10 (6.9) 0.982
Current cannabis use disorder 7 (9.6) 5 (6.9) 12 (8.3) 0.782
PTSD 6 (8.2) 3 (4.2) 9 (6.2) 0.494
Anxiety disorder 28 (38.4) 13 (18.1) 41 (28.3) 0.011
Major depressive disorder 30 (41.1) 25 (34.7) 55 (37.9) 0.536
Bipolar disorder 2 (2.7) 2 (2.8) 4 (2.8) 1.000
Personality disorder 2 (2.7) 1 (1.4) 3 (2.1) 1.000
History of suicide attempt 11 (15.1) 9 (12.5) 20 (13.8) 0.836
History of inpatient psychiatric treatment 11 (15.1) 6 (8.3) 17 (11.7) 0.316
History of residential or partial hospitalization program 2 (2.7) 3 (4.2) 5 (3.4) 0.681
Current psychotherapist 47 (64.4) 42 (58.3) 89 (61.4) 0.564
Current psychopharmacologist 36 (49.3) 29 (40.3) 65 (44.8) 0.354
Psychiatrist integrated with primary care 3 (4.1) 3 (4.2) 6 (4.1) 1.000
Addictions program integrated with primary care 0 (0.0) 2 (2.8) 2 (1.4) 0.245
Psychiatrist elsewhere 22 (30.1) 13 (18.1) 35 (24.1) 0.132
Current case management utilization 18 (24.7) 15 (20.8) 33 (22.8) 0.723
Bold indicates statistical signiﬁcance ( p < 0.05). Reported p-values are from Fisher’s exact tests wherein cell sizes are small (<5). Response rate was
100% for all variables except where table states ‘‘Not indicated.’’
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For the continuous outcome variable ‘‘age of hor-
mone therapy initiation,’’ given its distribution and dis-
persion, negative binomial multivariable regression
models were ﬁt to examine factors associated with this
outcome variable. Data analysis was conducted using
SAS Studio, Release 3.5, and Microsoft Excel 2010.
Results
Descriptive and bivariate analyses
Characteristics of the study sample are presented in
Tables 1–4 for TM and TF participants separately,
and for the total sample in aggregate. Also included
in these tables are bivariate statistics comparing TM
versus TF individuals.
Demographics. Overall, 50% of the sample was TM
participants and 50% TF participants. The mean age
of participants was 31.8 (SD= 11.5) years. The difference
in median age between TM participants (25 years old)
and TF participants (30 years old) was statistically sig-
niﬁcant (Mann–WhitneyU= 1753, p= 0.001). Four per-
cent of the sample identiﬁed as African American/black,
3% identiﬁed as Latinx/Hispanic, and 8% identiﬁed as
multiracial. Forty-one percent of the sample reported
living at or below the federal poverty level (Table 1).
Gender identity-related characteristics. Nearly one in
four (24.1%) patients identiﬁed as genderqueer/nonbi-
nary, in roughly equal proportions for TM (26.0%) and
TF (22.2%). Within the study sample, 95% of participants
were actively prescribed gender-afﬁrming hormones by
their primary care provider. The mean age of hormone
therapy initiation was 31.8 (SD= 11.1) years. The differ-
ence inmedian age of hormone therapy initiation between
TM participants (24 years old) and TF participants
(27 years old)was statistically signiﬁcant (Mann–Whitney
U= 1802.5, p= 0.001). TF participants were more likely
than TM participants to have a history of medically un-
monitored hormone use, and this difference was statisti-
cally signiﬁcant, w2 (2,N= 145)= 4.42, p< 0.013 (Table 2).
Thirty-two percent of participants had a history of
gender-afﬁrming surgery. Among TM participants,
37% had a history of gender-afﬁrming surgery, with
35.6% undergoing chest construction, 5.5% undergoing
hysterectomy, and 5.5% undergoing oophorectomy. In
addition, 1 TM patient in the original sample of 201
adults had undergone phalloplasty and was excluded
from multivariable regression procedures due to not
having complete data for all desired variables. Among
TF, 27.8% had a history of gender-afﬁrming procedures,
with 8.3% undergoing breast augmentation, 6.9% under-
going vaginoplasty, 2.8% undergoing facial feminization,
2.8% undergoing orchiectomy without vaginoplasty,
and 12.5% undergoing other gender-afﬁrming proce-
dures (i.e., other implants or electrolysis).
Sexual history. The most commonly reported sexual
orientation was ‘‘something else’’ (33.8%). Substantial
heterogeneity in the distribution of sexual orientation
was found by gender identity, w2 (4, N= 145)= 11.76,
p= 0.019, with a higher proportion of TM versus TF en-
dorsing ‘‘something else’’ (42.5% vs. 25.0%) or ‘‘straight’’
(20.5% vs. 12.5%), and a higher proportion of TF versus
TM identifying as ‘‘bisexual’’ (30.6% vs. 12.3%) or ‘‘does
not know’’ (11.1% vs. 5.5%). The majority of the sample
(62.1%) had a primary sex partner, 6.9% reported one or
more casual sex partners, and 13.8% had a sexually
transmitted infection diagnosis history (Table 3).
Mental health. Substance use disorders and other
psychiatric diagnoses were high in the sample, with
more than half (57.2%) diagnosed with a psychiatric
disorder. TM participants were more likely than TF
participants to have an anxiety disorder, and this differ-
ence was statistically signiﬁcant, w2 (1, N= 145)= 6.40,
p < 0.011 (Table 4).
Multivariable regression models
Table 5 presents multivariable logistic regression mod-
eling with history of any gender-afﬁrming surgery as
the primary outcome. Factors associated with a statisti-
cally signiﬁcant increase in the odds of undergoing
gender-afﬁrming surgery (at p< 0.05) were (1) age in
years, (2) income >300% of the federal poverty level,
Table 5. Signiﬁcant Outcomes of Binary Logistic
Regressions on History of Any Gender-Afﬁrming Surgery
Variable
Bivariate models Multivariable model
OR (95% CI) p aOR (95% CI) p
Demographics
Age in years 1.04 (1.01–1.07) 0.021 1.03 (1.00–1.07) 0.047
Income at 100–200%
of poverty level
0.21 (0.05–0.96) 0.044
Income >300%
of poverty level
2.76 (1.27–6.01) 0.011 3.17 (1.34–7.52) 0.009
Sexual history
Bisexual 0.33 (0.12–0.92) 0.035 0.23 (0.07–0.71) 0.011
Straight/heterosexual 2.46 (1.01–5.99) 0.048
Mental health
Current
psychotherapist
0.41 (0.20–0.83) 0.014 0.35 (0.16–0.76) 0.008
N= 145. Bold indicates statistical signiﬁcance ( p< 0.05).
aOR, adjusted odds ratio; 95%CI, 95% conﬁdence interval; OR, odds ratio.
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(3) not identifying as bisexual, and (4) not having a
current psychotherapist.
For the multivariable negative binomial regression
model given inTable 6, the primary outcome is age of ini-
tiation of gender-afﬁrming hormone therapy. There was
a statistically signiﬁcant association (at p< 0.05) between
younger age at time of hormone therapy initiation and
each of the following factors: (1) being TM, (2) being a
student, (3) identifying as straight/heterosexual, (4) hav-
ing casual sex partner(s), and (5) having no past alcohol
use disorder.
Discussion
In this EHR review study based at an LGBT-focused
urban health center, almost all transgender adults
were receiving gender-afﬁrming hormone therapy
from their primary care provider, similar to the high
prevalence of prescribed hormone therapy in other
samples of transgender adults from specialized clinical
settings.29–31 Compared with TM participants, we
found that TF participants were ﬁrst prescribed
gender-afﬁrming hormone therapy at an older age
and also had a greater likelihood of past medically un-
monitored hormone use. These differences may be re-
lated to TF participants being older than TM
participants in the sample (e.g., age cohort effects) or
to higher prevalence of discriminatory experiences
and/or more barriers to accessing gender-afﬁrming
health services among TF people.32 Our ﬁndings are
consistent with previous reports indicating that medi-
cally unmonitored hormone use among TF people typ-
ically occurs in the context of signiﬁcant barriers to
accessing and receiving gender-afﬁrming medical
care.15,18,33,34 The results in this study extend ﬁndings
from previous research with TF people that showed
prevalence of medically unmonitored hormone use as
high as 60% in the United States and Canada.13,15,34,35
Within our study sample, 32% of participants had a
documented history of gender-afﬁrming surgery. This
ﬁnding is similar to a recent retrospective chart review
conducted at a specialized endocrinology clinic where
35% of transgender patients had a history of gender-
afﬁrming surgery.36 Consistent with our study, this
chart review found that TM patients underwent chest
construction surgery more often than hysterectomy
and/or oophorectomy, and that TF patients underwent
either breast augmentation or genital surgery more
often than facial feminization surgery. A recent survey
study of both TM and TF adults found that 23% of re-
spondents reported past chest surgery and 11%
reported past genital reconstruction surgery.22 In con-
trast to that study, our analysis did not exclude the
large subgroup of participants (24.1%) with nonbinary
gender identities (e.g., genderqueer), who often face
unique barriers to receiving gender-afﬁrming surgeries
in the context of surgical prerequisites that may favor
candidates with more traditional binary gender identi-
ties.2 To our knowledge, no studies to date have
assessed whether nonbinary transgender adults are as
likely to seek gender-afﬁrming surgeries as their coun-
terparts with binary gender identities.
We found that transgender adults with a history of
gender-afﬁrming surgery were more likely to be older
and to have a higher income than those without a his-
tory of gender-afﬁrming surgery. Based on EHR data,
we were unable to consistently assess age at time of
Table 6. Signiﬁcant Outcomes of Negative Binomial Regressions on Age of Hormone Therapy Initiation
Variable
Bivariate models Multivariable model
Coefficient (95% CI) p Coefficient (95% CI) p
Demographics
Male sex assigned at birth (i.e., TF) 0.24 (0.13–0.34) <0.001 0.21 (0.11–0.31) <0.001
Student status 0.21 (0.38 to0.04) 0.013 0.16 (0.31 to0.01) 0.041
Income >300% of poverty level 0.14 (0.01–0.27) 0.030
Gender identity-related characteristics
Male gender identity 0.17 (0.29 to0.06) 0.002
Sexual history
Straight/heterosexual 0.17 (0.33 to0.02) 0.024 0.15 (0.28 to0.01) 0.032
Casual sex partner(s) 0.28 (0.50 to0.05) 0.017 0.31 (0.51 to0.10) 0.003
Mental health
Past alcohol use 0.20 (0.01– 0.39) 0.035
Lifetime substance use disorder 0.15 (0.02–0.29) 0.026
Current alcohol use disorder 0.22 (0.02–0.43) 0.031
Past alcohol use disorder 0.30 (0.09–0.51) 0.005 0.27 (0.08–0.45) 0.005
N= 145. Bold indicates statistical signiﬁcance ( p< 0.05).
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ﬁrst gender-afﬁrming surgery and whether this age was
associated with prior duration of engagement in
gender-afﬁrming hormone therapy. Older transgender
adults are developmentally more likely to have estab-
lished the ﬁnancial security, psychosocial stability,
and support networks to facilitate effectively accessing
gender-afﬁrming surgical care, even in the context of
recent expansion of insurance coverage for gender-
afﬁrming surgical procedures in the United States.19,37
It is also possible that transgender people who undergo
gender-afﬁrming surgery may be more capable of in-
creasing their incomes because of the higher quality
of life and improved functioning observed among
transgender adults after accessing gender-afﬁrming
care.4 In the context of prior research showing that
transgender adults in the United States on the low
end of the socioeconomic status (SES) spectrum (e.g.,
low income) report higher rates of lifetime refusal of
healthcare than those of higher SES,38 our ﬁndings
point to an SES gradient in access to gender-afﬁrming
surgeries, with disparities in access for low-income
transgender adults.
Bisexual-identiﬁed participants in this sample were
less likely to have had gender-afﬁrming surgery.
Some experts on the topic of sexuality among transgen-
der people have pointed to the adverse impact of med-
ical gatekeeping by clinicians who historically viewed a
‘‘non-normative’’ sexual orientation (e.g., not ‘‘straight’’
or ‘‘heterosexual’’) as an ineligibility criterion for
gender-afﬁrming body modiﬁcations.39 The EHR data
did not afford us the opportunity to assess differences
based on sexual orientation in the likelihood of seeking
gender-afﬁrming surgery. Not currently having a psy-
chotherapist was associated with a history of gender-
afﬁrming surgery. The lower likelihood of having a
psychotherapist among participants with past gender-
afﬁrming surgery may be related to the high degree
of psychiatric stability typically required to access
gender-afﬁrming surgical procedures,2 consistent with
previous research indicating that the presence of a
mood disorder is associated with a longer time lag be-
tween initially presenting for gender-afﬁrming outpa-
tient care and ultimately accessing gender-afﬁrming
genital surgery.40 Alternatively, this result may be due
to signiﬁcant improvement in psychological function-
ing among transgender people whose gender has been
afﬁrmed through access to healthcare.4
This study also assessed age of initiation of gender-
afﬁrming hormone prescriptions. Transgender adults
who accessed hormone prescriptions early in life
were more likely to be TM and to be a student. It
may be that transgender participants who accessed
hormone prescriptions at a younger age were more
likely to be TM in light of greater stigma and barriers
to healthcare linkage experienced by TF people.32 Stu-
dent status among transgender adults may be a marker
of higher educational and economic status associated
with greater health literacy and ﬁnancial resources,
which could facilitate earlier access to hormone pre-
scriptions. Another possibility is that access to gender-
afﬁrming hormone prescriptions early in life led to
enhanced psychological functioning and, therefore,
more advanced subsequent educational attainment.4
With regard to sexual history, accessing hormone
prescriptions at younger ages was associated with iden-
tifying as straight/heterosexual and having casual sex
partner(s). Transgender participants with societally de-
ﬁned normative sexual orientations (e.g., ‘‘straight’’ or
‘‘heterosexual’’ people) may have encountered less
medical gatekeeping when seeking hormone prescrip-
tions early in life from clinicians who viewed their
more traditional sexuality as an indicator of the appro-
priateness of their transgender identity.39 It is also possi-
ble that transgender adults who are not heterosexual- or
straight-identiﬁed tend to seek hormone therapy later in
life or with lower prevalence, or that among transgender
adults this subpopulation encounters more barriers to
healthcare access in general. Accessing gender-afﬁrming
hormone prescriptions early in life may have been as-
sociated with having one or more casual sex partners
due to greater comfort engaging in sexual activity
among transgender adults after accessing medical gen-
der afﬁrmation.41–43
In terms of mental health, younger age of hormone
prescription access was associated with not having a
past alcohol use disorder. Participants who accessed
gender-afﬁrming hormones at a younger age may
have had less of the behavioral disorganization or
clinician-level gatekeeping that can occur in the context
of an alcohol use disorder and impede linkage to
gender-afﬁrming medical care. Alternatively, transgen-
der adults with access to gender-afﬁrming hormones at
an earlier age may have subsequently experienced less
gender dysphoria and, therefore, been less likely to
cope with gender-related distress by means of at-risk
alcohol use.2,9,32 That younger age of hormone therapy
initiation was protective for alcohol use disorder sug-
gests that early access to gender-afﬁrming hormones
may buffer against subsequent adverse substance use
disorder outcomes.
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A limitation of this study is its cross-sectional design,
which does not permit causal inference about the rela-
tionships of independent variables to past gender-
afﬁrming surgery or age of hormone therapy initiation.
Another limitation of our work is the derivation of this
study sample of transgender adults from one LGBT-
specialized urban community health center in the
United States with a primarily white patient popula-
tion, which reduces our ability to generalize these ﬁnd-
ings to all transgender communities in any region. The
retrospective EHR review method is susceptible to un-
intended bias related to documentation that may be in-
complete, clinical information that may not have been
recorded, and subjective interpretation of some vari-
ables of interest from the charts (e.g., deﬁning ‘‘casual’’
and ‘‘primary’’ sex partners).26,27,44–46 Individual vari-
ability among members of the clinical care team in
their practice of entering information into EHR ﬁelds
may have also diminished data integrity.47 Finally,
stigma was not assessed as part of this study because
this information is not captured in EHRs. Future re-
search would beneﬁt from considering the role of
stigma in access to and receipt of gender-afﬁrming hor-
mones and surgical interventions.48
Conclusion
Although not without limitations, this study extends
our understanding of the prevalence of gender-
afﬁrming surgeries and age of hormone therapy initia-
tion among both TM and TF adults. Our ﬁndings sug-
gest that accessing these gender-afﬁrming treatments is
associated with better mental health, higher socioeco-
nomic status, and having a heterosexual orientation.
To our knowledge, this is the ﬁrst study to comprehen-
sively examine the relationship of these two categories of
gender-afﬁrming clinical care with demographics, gen-
der identity, sexual history, and mental health. An addi-
tional strength of our research is that approximately
one-quarter of the study sample were genderqueer/non-
binary patients at the time of clinical care initiation at
the health center, offering greater heterogeneity of gen-
der identities in the sample and reﬂecting the reality of
clinical practices serving transgender patients. Our
study also serves as a demonstration of how systematic
gender identity data collection in EHRs provides oppor-
tunities to better understand the unique health needs of
transgender people engaged in clinical care. Future stud-
ies ought to continue to focus on barriers and facilitators
of gender-afﬁrming care for transgender adults, to facil-
itate the development of individual- and systems-level
interventions, as well as policies, that help expand access
to medically necessary care for this highly underserved
and vulnerable population, reduce health disparities,
and improve both physical and mental health outcomes.
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